|
China Medical System Holdings Limited (0867.HK) Valoración de DCF |
Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
Predeterminadas Para Un Uso Rápido Y Eficiente
Compatible con MAC / PC, completamente desbloqueado
No Se Necesita Experiencia; Fáciles De Seguir
China Medical System Holdings Limited (0867.HK) Bundle
¡Mejore sus opciones de inversión con la calculadora DCF de China Medical System Holdings Limited (0867HK)! Explore datos financieros auténticos, ajuste las proyecciones y gastos de crecimiento, y observe instantáneamente cómo estas modificaciones afectan el valor intrínseco de China Medical System Holdings Limited (0867HK).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,371.7 | 8,848.2 | 9,711.2 | 8,504.4 | 7,926.8 | 8,136.1 | 8,351.0 | 8,571.5 | 8,797.9 | 9,030.2 |
| Revenue Growth, % | 0 | 20.03 | 9.75 | -12.43 | -6.79 | 2.64 | 2.64 | 2.64 | 2.64 | 2.64 |
| EBITDA | 3,239.0 | 3,931.7 | 4,085.6 | 3,101.2 | 2,449.6 | 3,218.9 | 3,303.9 | 3,391.1 | 3,480.7 | 3,572.6 |
| EBITDA, % | 43.94 | 44.44 | 42.07 | 36.47 | 30.9 | 39.56 | 39.56 | 39.56 | 39.56 | 39.56 |
| Depreciation | 221.1 | 233.3 | 241.2 | 222.1 | 275.1 | 231.1 | 237.2 | 243.5 | 249.9 | 256.5 |
| Depreciation, % | 3 | 2.64 | 2.48 | 2.61 | 3.47 | 2.84 | 2.84 | 2.84 | 2.84 | 2.84 |
| EBIT | 3,017.9 | 3,698.4 | 3,844.5 | 2,879.1 | 2,174.5 | 2,987.8 | 3,066.7 | 3,147.7 | 3,230.8 | 3,316.1 |
| EBIT, % | 40.94 | 41.8 | 39.59 | 33.85 | 27.43 | 36.72 | 36.72 | 36.72 | 36.72 | 36.72 |
| Total Cash | 2,836.1 | 4,631.1 | 6,227.3 | 6,519.8 | 6,226.2 | 5,046.8 | 5,180.1 | 5,316.9 | 5,457.3 | 5,601.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,805.5 | 2,302.1 | 2,164.7 | 1,842.3 | .0 | 1,537.1 | 1,577.7 | 1,619.4 | 1,662.2 | 1,706.1 |
| Account Receivables, % | 24.49 | 26.02 | 22.29 | 21.66 | 0 | 18.89 | 18.89 | 18.89 | 18.89 | 18.89 |
| Inventories | 404.6 | 501.6 | 506.5 | 676.7 | 815.2 | 563.2 | 578.1 | 593.4 | 609.1 | 625.1 |
| Inventories, % | 5.49 | 5.67 | 5.22 | 7.96 | 10.28 | 6.92 | 6.92 | 6.92 | 6.92 | 6.92 |
| Accounts Payable | 143.1 | 154.8 | 188.9 | 150.3 | 151.2 | 151.5 | 155.5 | 159.6 | 163.8 | 168.2 |
| Accounts Payable, % | 1.94 | 1.75 | 1.95 | 1.77 | 1.91 | 1.86 | 1.86 | 1.86 | 1.86 | 1.86 |
| Capital Expenditure | -362.3 | -196.2 | -557.1 | -337.4 | -483.9 | -373.3 | -383.2 | -393.3 | -403.7 | -414.3 |
| Capital Expenditure, % | -4.92 | -2.22 | -5.74 | -3.97 | -6.1 | -4.59 | -4.59 | -4.59 | -4.59 | -4.59 |
| Tax Rate, % | 19.43 | 19.43 | 19.43 | 19.43 | 19.43 | 19.43 | 19.43 | 19.43 | 19.43 | 19.43 |
| EBITAT | 2,711.7 | 3,228.5 | 3,329.7 | 2,405.4 | 1,752.1 | 2,556.8 | 2,624.3 | 2,693.7 | 2,764.8 | 2,837.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 503.5 | 2,683.8 | 3,180.3 | 2,403.7 | 3,247.9 | 1,129.8 | 2,426.9 | 2,491.0 | 2,556.8 | 2,624.3 |
| WACC, % | 8.24 | 8.23 | 8.23 | 8.23 | 8.22 | 8.23 | 8.23 | 8.23 | 8.23 | 8.23 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 8,711.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 2,677 | |||||||||
| Terminal Value | 42,961 | |||||||||
| Present Terminal Value | 28,928 | |||||||||
| Enterprise Value | 37,639 | |||||||||
| Net Debt | -3,020 | |||||||||
| Equity Value | 40,660 | |||||||||
| Diluted Shares Outstanding, MM | 2,427 | |||||||||
| Equity Value Per Share | 16.75 |
Benefits You Will Receive
- Genuine CMS Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-time Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Explore various scenarios to assess the future performance of China Medical System Holdings Limited (0867HK).
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Customizable Forecast Parameters: Easily adjust essential inputs such as revenue growth rates, EBITDA percentages, and capital expenditures.
- Automated DCF Valuation: Instantly computes intrinsic value, NPV, and other financial outputs.
- High-Precision Accuracy: Leverages China Medical System Holdings Limited’s real-world financial data for accurate valuation results.
- Simplified Scenario Analysis: Effortlessly evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Streamlines the process by removing the necessity of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review the pre-filled data for China Medical System Holdings Limited (0867HK) (historical and projected).
- Step 3: Modify the key assumptions (yellow cells) according to your analysis.
- Step 4: Observe automatic recalculations for the intrinsic value of China Medical System Holdings Limited (0867HK).
- Step 5: Utilize the results for investment decisions or reporting.
Why Opt for This Calculator?
- Precision: Utilizes genuine China Medical System Holdings Limited (0867HK) financials to ensure accurate data.
- Adaptability: Built to allow users to experiment and adjust inputs with ease.
- Efficiency: Eliminate the complexities of creating a DCF model from the ground up.
- High-Quality: Crafted with precision and usability, suitable for CFO-level analysis.
- Intuitive: Simple to navigate, even for those lacking extensive financial modeling experience.
Who Can Benefit from This Product?
- Investors: Evaluate the valuation of China Medical System Holdings Limited (0867HK) before making investment decisions.
- CFOs and Financial Analysts: Enhance valuation workflows and validate financial forecasts.
- Startup Founders: Gain insights into how leading public companies like China Medical System Holdings Limited (0867HK) are assessed.
- Consultants: Provide comprehensive valuation reports tailored for client needs.
- Students and Educators: Utilize authentic data to practice and instruct on valuation methodologies.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for China Medical System Holdings Limited (0867HK), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models that provide intrinsic value calculations with comprehensive detail.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate thorough analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios specific to China Medical System Holdings Limited (0867HK).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions, designed for easy results analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.